|
29 Nov 2022 |
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
|
|
29 Nov 2022 |
AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
|
|
21 Nov 2022 |
Merck to Acquire Imago BioSciences, Inc.
|
|
17 Nov 2022 |
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
|
|
15 Nov 2022 |
Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases
|
|
14 Nov 2022 |
Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases
|
|
14 Nov 2022 |
Ionis partners with Metagenomi to add gene editing to its broad technology platform
|
|
13 Nov 2022 |
Emerging Novel RNA-Targeted Drug Modalities Open the Door for Novel Treatments
|
|
10 Nov 2022 |
Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
|
|
04 Nov 2022 |
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
|
|
01 Nov 2022 |
Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets
|
|
30 Oct 2022 |
PhoreMost enters multi-target collaboration with targeted protein degradation leader Arvinas
|
|
27 Oct 2022 |
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
|
|
27 Oct 2022 |
CSL enters into Strategic Option and License Agreement with Translational Sciences
|
|
26 Oct 2022 |
Radiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225
|
|
26 Oct 2022 |
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
|
|
26 Oct 2022 |
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs
|
|
25 Oct 2022 |
Syncona to Acquire Applied Genetic Technologies Corporation
|
|
25 Oct 2022 |
Sauvie Inc. Enters into an Exclusive Worldwide License Agreement to Develop and Commercialize a Nanobody-based NK Cell Engager
|
|
24 Oct 2022 |
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
|
|
21 Oct 2022 |
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
|
|
21 Oct 2022 |
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
|
|
21 Oct 2022 |
AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline
|
|
21 Oct 2022 |
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
|
|
20 Oct 2022 |
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
|
